In the New Era of ASCVD Lipid Risk Management: You Manage the Case

The therapeutic landscape for ASCVD is evolving rapidly. Stay ahead of the clinical curve with this interactive case-based broadcast featuring renowned cardiovascular experts sharing the latest evidence-based standards of practice in ASCVD risk reduction and treatment.   

Live Broadcast
1.50 available credits
Information
May 19, 2020
01:00 PM - 03:00 PM EDT
Online
In the New Era of ASCVD Lipid Risk Management: You Manage the Case
Choose a format
Details
Presenters
Related
Comments
  • Overview

    This engaging virtual program features 4 nationally recognized experts in the management of ASCVD risk assessment and treatment, sharing exciting updates on emerging therapeutic options stemming from late-breaking clinical trials. Case-based learning models will simulate and apply key concepts into clinical practice.

    Once registered, please be on the lookout for a confirmation email with testing instructions. 

  • Program Schedule

    1:00 pm–1:10 pm

    Welcome, Introductions, Program Overview, and Pre-Activity Test Questions
    Michael Miller, MD, FACC, FAHA - Chair

    1:10 pm–1:30 pm

    Update on Determining Risk Status in ASCVD
    James A. Underberg, MD, MS, FACP, FNLA

    1:30 pm–1:50 pm

    New Approaches to the Management of Patients at High-Risk of CVD Events
    Karol Watson, MD, PhD, FACC

    1:50 pm–2:15 pm

    Managing ASCVD Risk Beyond LDL-C Lowering Therapy
    Michael Miller, MD, FACC, FAHA - Chair

    2:15 pm–2:35 pm

    Practical Considerations to Manage Residual Risk
    Sergio Fazio, MD, PhD

    2:35 pm–2:55 pm

    Discussion and Question & Answers
    Michael Miller, MD, FACC, FAHA - Chair
    Sergio Fazio, MD, PhD
    James A. Underberg, MD, MS, FACP, FNLA
    Karol Watson, MD, PhD, FACC

    2:55 pm–3:00 pm

    Closing Comments, and Adjourn
    Michael Miller, MD, FACC, FAHA - Chair

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Have greater clarity on risk assessment and management based on the 2018 AHA/ACC/Multiple Society Guideline on the Management of Blood Cholesterol
    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and utility of ASCVD therapies in practice
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Target Audience

    This course is designed to meet the continuing medical education needs of the Internal Medicine and Primary Care Physicians and allied health professionals who treat patients with, or at high risk of, ASCVD.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    For all devices:

    • Hardwired Ethernet connection is preferred, when available. Wi-Fi is also supported
    • A headset with an attached microphone is preferred for best quality audio
    • Working webcam

    Please note that the Logitech C920 and C930 models are NOT supported by Pando. 
    If you have one of these Logitech webcams, please plan to replace prior to the meeting

    Windows PC:

    Macintosh:

    • OS 10.13 or higher
    • Google Chrome or Safari
    • Mozilla Firefox also supported

    iPad:

    • iOS 11 or higher
    • Safari

Facebook Comments

Details
Presenters
Related
Comments
  • Overview

    This engaging virtual program features 4 nationally recognized experts in the management of ASCVD risk assessment and treatment, sharing exciting updates on emerging therapeutic options stemming from late-breaking clinical trials. Case-based learning models will simulate and apply key concepts into clinical practice.

    Once registered, please be on the lookout for a confirmation email with testing instructions. 

  • Program Schedule

    1:00 pm–1:10 pm

    Welcome, Introductions, Program Overview, and Pre-Activity Test Questions
    Michael Miller, MD, FACC, FAHA - Chair

    1:10 pm–1:30 pm

    Update on Determining Risk Status in ASCVD
    James A. Underberg, MD, MS, FACP, FNLA

    1:30 pm–1:50 pm

    New Approaches to the Management of Patients at High-Risk of CVD Events
    Karol Watson, MD, PhD, FACC

    1:50 pm–2:15 pm

    Managing ASCVD Risk Beyond LDL-C Lowering Therapy
    Michael Miller, MD, FACC, FAHA - Chair

    2:15 pm–2:35 pm

    Practical Considerations to Manage Residual Risk
    Sergio Fazio, MD, PhD

    2:35 pm–2:55 pm

    Discussion and Question & Answers
    Michael Miller, MD, FACC, FAHA - Chair
    Sergio Fazio, MD, PhD
    James A. Underberg, MD, MS, FACP, FNLA
    Karol Watson, MD, PhD, FACC

    2:55 pm–3:00 pm

    Closing Comments, and Adjourn
    Michael Miller, MD, FACC, FAHA - Chair

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Have greater clarity on risk assessment and management based on the 2018 AHA/ACC/Multiple Society Guideline on the Management of Blood Cholesterol
    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and utility of ASCVD therapies in practice
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Target Audience

    This course is designed to meet the continuing medical education needs of the Internal Medicine and Primary Care Physicians and allied health professionals who treat patients with, or at high risk of, ASCVD.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    For all devices:

    • Hardwired Ethernet connection is preferred, when available. Wi-Fi is also supported
    • A headset with an attached microphone is preferred for best quality audio
    • Working webcam

    Please note that the Logitech C920 and C930 models are NOT supported by Pando. 
    If you have one of these Logitech webcams, please plan to replace prior to the meeting

    Windows PC:

    Macintosh:

    • OS 10.13 or higher
    • Google Chrome or Safari
    • Mozilla Firefox also supported

    iPad:

    • iOS 11 or higher
    • Safari

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free